Log In
BCIQ
Print this Print this
 

Lanthionine-galanin/Gal2 agonist

  Manage Alerts
Collapse Summary General Information
Company MorphoSys AG
DescriptionLantipeptide
Molecular Target Galanin receptor 2 (GALR2)
Mechanism of Action 
Therapeutic ModalityPeptide

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$22.3M

$22.3M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/07/2015

$22.3M

$22.3M

0

Get a free BioCentury trial today